Latest Personalis news, funding rounds and robotics & AI coverage. 1 article tracked by The Robotics Media.
Personalis (NASDAQ: PSNL), based in Fremont, California, develops advanced tumor-informed cancer genomics tests. Its flagship NeXT Personal® MRD assay detects trace amounts of circulating tumor DNA — helping clinicians track treatment response, identify residual disease and catch recurrence earlier than conventional imaging. The company holds Medicare coverage across multiple indications and, in July 2026, agreed to be acquired by Tempus AI for $1.5 billion.